



3rd January 2017

Half-year review of the liquidity contract

Relating to the liquidity contract established by **AMOEBBA** with PORTZAMPARC Trading Company, the liquidity account held the following amounts on **31st December 2016**:

- **9,749 AMOEBA shares,**
- **70,243.29 euros.**

As a reminder, at the time of **implementation**, the following amounts were present in the liquidity account:

- **200,000.00 euros.**



About AMOEBA: AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector and complies with the new regulations in terms of chemical emissions into the environment. In a worldwide market for chemical biocides estimated to be worth EUR 21 bn⁽¹⁾, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT), estimated to be worth EUR 1.7bn⁽²⁾. AMOEBA is pursuing the regulatory procedures to obtain the provisional MA for all European countries in “Cooling Towers” application. Based in Chassieu – France. AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index. For more information: www.amoeba-biocide.com.

(1) : Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2) : Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

Contacts :

Amoeba

Nathalie COMBROUSSE
Marketing Communication Manager
+33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin

Ghislaine GASPARETTO
Financial Communication
+33(0)1 56 88 11 11
ggasparetto@actifin.fr